Sign In
Buy GMED
$86.15
+3.80 (+4.61%)
At Close: Aug 10, 2026
Reasons to Retain Globus Medical Stock in Your Portfolio for Now
10:36am, Wednesday, 22'nd Jul 2026
GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.
3 Medical Device Stocks Giving Investors a Different Healthcare Play
09:40am, Monday, 20'th Jul 2026
When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical device
GMED Stock Surges 43.6% in a Year: What's Driving the Rally?
03:21pm, Friday, 17'th Jul 2026
Globus Medical's 43.6% one-year rally is fueled by strong growth across both business segments, rising technology adoption and a debt-free balance sheet.
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
09:02pm, Thursday, 16'th Jul 2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
04:30pm, Thursday, 16'th Jul 2026
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30
Here's Why Globus Medical (GMED) is a Strong Value Stock
10:40am, Thursday, 16'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
10:51am, Wednesday, 01'st Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED vs. MDT: Which Medical Stock Has More Upside Potential?
02:41pm, Monday, 29'th Jun 2026
Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
10:41am, Friday, 26'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 22'nd Jun 2026
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
11:31am, Monday, 22'nd Jun 2026
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
07:40am, Monday, 22'nd Jun 2026
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas
Here's How Innovation Fuels Globus Medical's Growth Momentum
11:36am, Monday, 15'th Jun 2026
GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
08:00am, Friday, 12'th Jun 2026
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its res
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
11:06am, Tuesday, 09'th Jun 2026
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
